Sharekhan

Thyrocare Technologies Ltd

Fri 22/05/2026,15:57:54 | NSE : THYROCARE

₹ 465.85-3.20 (-0.68%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 469.95

Previous Close

₹ 469.05

Volume

121276

Mkt Cap ( Rs. Cr)

₹7414.72

High

₹ 469.95

Low

₹ 460.10

52 Week High

₹ 536.13

52 Week Low

₹ 291.08

Book Value Per Share

₹ 41.98

Dividend Yield

3.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Thyrocare Technologies Ltd

Your Vote -

Buy

78.85%

Hold

7.69%

Sell

13.46%

78.85%

52 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

465.85

296

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

296

Option Chain

Analyzes market sentiment, predicts Thyrocare Technologies Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Thyrocare Tech. - Disclosure under SEBI Takeover Regulations

    21 May 2026, 10:49AM Docon Technologies Private Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of I
  • Thyrocare Tech. - Analysts/Institutional Investor Meet/Con. Call Updates

    14 May 2026, 1:09PM Thyrocare Technologies Limited has informed the Exchange about Transcript
  • Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    14 May 2026, 1:07PM Please find attached the Earnings Call Transcript held on May 12, 2026
  • Thyrocare Tech. - Analysts/Institutional Investor Meet/Con. Call Updates

    12 May 2026, 2:19PM Thyrocare Technologies Limited has informed the Exchange about Link of Recording
  • Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    12 May 2026, 2:20PM Please find attached herewith Link of Audio Recording for Investor Call held on May 12, 2026
  • Thyrocare Tech. - Copy of Newspaper Publication

    9 May 2026, 12:36PM Thyrocare Technologies Limited has informed the Exchange about Copy of Newspaper Publication of Audited financial results for the quarter and year end
  • Thyrocare Tech. - Analysts/Institutional Investor Meet/Con. Call Updates

    7 May 2026, 9:42PM Thyrocare Technologies Limited has informed the Exchange about Schedule of meet
  • Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    7 May 2026, 9:39PM Please find attached Intimation for analyst/investor Earning conference call on the Audited Financial Results of the Company for the financial year en
  • Thyrocare Tech. - Resignation of Director/KMP/SMP

    7 May 2026, 8:39PM Thyrocare Technologies Limited has informed the Exchange about Resignation of Director/KMP/SMP
  • Thyrocare Tech. - Acquisition

    7 May 2026, 8:17PM Thyrocare Technologies Limited has informed the Exchange about equity infusion in Think Health Diagnostics Private Limited, wholly owned subsidiary of
  • Thyrocare Tech. - Outcome of Board Meeting

    7 May 2026, 8:13PM Thyrocare Technologies Limited has informed the Exchange regarding amendments to the Memorandum of Association of the Company.
  • Thyrocare Tech. - Change in Auditors

    7 May 2026, 8:09PM Thyrocare Technologies Limited has informed the Exchange regarding Change in Auditors of the company.
  • Thyrocare Tech. - Change in Director(s)

    7 May 2026, 8:06PM Thyrocare Technologies Limited has informed the Exchange regarding Change in Director(s) of the company.
  • Thyrocare Tech. - Resignation

    7 May 2026, 8:04PM Thyrocare Technologies Limited has informed the Exchange regarding Resignation of Dharmil Nirupam Sheth and Dhaval Rajesh Shah as Non- Executive Dire
  • Thyrocare Tech. - Appointment

    7 May 2026, 8:00PM Thyrocare Technologies Limited has informed the Exchange regarding Re-appointment of Mr. Rahul Franklin Guha as Managing Director & CEO of the compan
  • Thyrocare Tech. - Appointment

    7 May 2026, 7:58PM Thyrocare Technologies Limited has informed the Exchange regarding Appointment of Mr. Uday Patel Kadam and Mr. Gaurav Verma as Non- Executive Directo
  • Thyrocare Tech. - Outcome of Board Meeting

    7 May 2026, 7:54PM Thyrocare Technologies Limited has informed the Exchange regarding change in Directors of the Company.
  • Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association

    7 May 2026, 7:50PM Please find attached herewith intimation regarding the Amendments to Memorandum of Association of the Company
  • Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Acquisition

    7 May 2026, 7:48PM The Board of Directors of the Company in its meeting held today i.e., May 07, 2026 has approved the equity infusion in Think Health Diagnostics Privat
  • Thyrocare Tech. - Appointment Of Cost Auditors For The Financial Year 2026-27

    7 May 2026, 7:46PM Please refer the enclosed intimation letter
  • Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s

    7 May 2026, 7:44PM Please refer the enclosed the intimation letter
  • Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Resignation of Director

    7 May 2026, 7:43PM Please refer the enclosed intimation letter
  • Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Change in Management

    7 May 2026, 7:42PM Please refer the enclosed intimation letter
  • Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Change in Directorate

    7 May 2026, 7:39PM Please find attached herewith intimation regarding change in directors of the Company
  • Thyrocare Tech. - Corporate Action-Board approves Dividend

    7 May 2026, 7:35PM The Board of Directors at its meeting held today i.e., May 07, 2026 has recommended the final dividend of Rs. 7 per equity share.
  • Thyrocare Tech. - Dividend

    7 May 2026, 7:27PM Thyrocare Technologies Limited has informed the Exchange that Board of Directors at its meeting held on May 07, 2026, recommended Final Dividend of Rs
  • Thyrocare Tech. - General Updates

    7 May 2026, 7:24PM Audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026
  • Thyrocare Tech. - Audited Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended On March 31,

    7 May 2026, 7:19PM Please find attached the Audited Financial Results for the quarter and financial year ended on March 31, 2026
  • Thyrocare Tech. - Press Release

    7 May 2026, 6:43PM Thyrocare Technologies Limited has informed the Exchange regarding Press release on Audited Standalone and Consolidated Financial Results for the quar
  • Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    7 May 2026, 6:38PM Please find attached press release on the Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended on March 31,
  • Thyrocare Tech. - Investor Presentation

    7 May 2026, 6:24PM Thyrocare Technologies Limited has informed the Exchange about Investor Presentation
  • Thyrocare Tech. Q4 net profit jumps 98.54% at Rs 43.58 cr

    7 May 2026, 6:20PM The company reported standalone net profit of Rs 43.58 crore for the quarter ended March 31, 2026 as compared to Rs 21.95 crore in the same period las
  • Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Investor Presentation

    7 May 2026, 6:20PM Please find enclosed the Investor Presentation on the Audited Financial Results for the quarter and financial year ended on March 31, 2026.
  • Thyrocare Tech. - Board Meeting Outcome for Outcome Of The Board Meeting Held On May 07, 2026

    7 May 2026, 6:00PM Please find enclosed the Outcome of the Board Meeting held on May 07, 2026, inter alia, for the approval of the Financial Results for the quarter and
  • Thyrocare Tech. - Outcome of Board Meeting

    7 May 2026, 5:58PM Outcome of Board Meeting held on May 07, 2026
  • Thyrocare Tech. - General Updates

    7 May 2026, 5:35PM Thyrocare Technologies Limited has informed the Exchange about cancellation of earning conference call
  • Thyrocare Tech. - Cancellation Of Earning Conference Call

    7 May 2026, 5:34PM Please refer the enclosed intimation
  • Thyrocare Tech. - Analysts/Institutional Investor Meet/Con. Call Updates

    4 May 2026, 6:19PM Thyrocare Technologies Limited has informed the Exchange about Schedule of meet
  • Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    4 May 2026, 5:59PM Updated Webcast Link for Investor Call: There has been a change in the webcast link in the earlier intimation made on April 29, 2026. The revised webc
  • Thyrocare Tech. - Analysts/Institutional Investor Meet/Con. Call Updates

    29 Apr 2026, 2:39PM Thyrocare Technologies Limited has informed the Exchange about Schedule of meet
  • Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    29 Apr 2026, 2:09PM Thyrocare Technologies Limited cordially invites you to its \Earning Call\ to be held on Thursday, May 07, 2026 at 05.30 p.m. to discuss the financial
  • Thyrocare Tech. - Corporate Action-Board to consider Dividend

    29 Apr 2026, 1:51PM Please find attached the Board Meeting Intimation to consider and recommend the Final Dividend for the financial year 2025-26
  • Thyrocare Tech. - Board Meeting Intimation for Consideration And Approval Of Audited Standalone And Consolidated Financial Re

    29 Apr 2026, 1:32PM Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/05/2026 ,inter alia, to consid
  • Thyrocare Tech. has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026

    13 Apr 2026, 5:10PM As of March 2026, 60.92% is owned by Indian Promoters and 39.08% by Public. <p align=justify> Institutional holds 26.37% (Insurance Companies 0.37%) a
  • Thyrocare Tech. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    6 Apr 2026, 8:02PM Thyrocare Technologies Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarte
  • Thyrocare Tech. - General Updates

    29 Mar 2026, 8:40PM Thyrocare Technologies Limited has informed the Exchange about Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements
  • Thyrocare Tech. - Trading Window

    23 Mar 2026, 3:52PM Thyrocare Technologies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regula
  • Thyrocare Tech. - ESOP/ESOS/ESPS

    2 Mar 2026, 3:26PM Thyrocare Technologies Limited has informed the Exchange for the allotment of 3,624 shares pursuant to the exercise of stock options under the Thyroca
  • Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    2 Mar 2026, 3:21PM Allotment of 3,624 equity shares under Thyrocare Employee Stock Option Scheme of the Company
  • Thyrocare Technologies Ltd

    29 Jan 2026 , 9:06AM Thyrocare : The company reported a strong performance for the December quarter, with net profit rising 36.7% year-on-year to ₹26.1 crore, compared with ₹19.1 crore in the same period last year, aided by higher volumes and operating leverage. Revenue growth stood at 17.8% at Rs 196 crore versus Rs 166 crore. EBITDA was up 38.6% at Rs 57.8 crore versus Rs 41.7 crore. EBITDA Margins came in at 29.6% versus 25.2% yoy.
  • Thyrocare Technologies

    15 Oct 2025 , 9:04AM Thyrocare Technologies : The company delivered a robust performance for the July-September quarter, with net profit soaring 82% year-on-year to Rs 47.90 crore, driven by a surge in test volumes and enhanced operational efficiency. The company's revenue rose 22%, reaching Rs 216.5 crore, up from Rs 177.4 crore in the same period last year. EBITDA witnessed a sharp 47.5% growth, coming in at Rs 71.3 crore, reflecting strong cost management and scale efficiencies. As a result, operating margins expanded significantly to 32.9%, compared to 27.2% in the year-ago quarter. The board also Ok’d 2:1 bonus share issue proposal. Positive
  • Thyrocare to acquire Vimta's Diagnostic & Pathological svcs business on a slump sale basis

    30 Aug 2024 , 12:00PM Thyrocare Technologies enters into a BTA to acquire diagnostic and pathological services business of Vimta Labs
  • Thyrocare Technologies

    28 Jun 2021 , 9:32AM The promoters and promoters group of the company have entered in to an agreement with Docon Technologies Private Limited (along with API Holdings Pvt Limited – Persons acting in concert) to sell their entire stake of 66.14% representing 3,49,72,999 equity shares in Thyrocare Technologies for a consideration of 4564 crs, translating to RS 1305 per equity share. Consequent to the execution of share purchase agreement, an open offer for acquisition of 1.37 crore shares of Thyrocare, representing 26% of the expanded voting share capital has been announced at a price of Rs 1300 per share, which is at a discount of 10.2% as compared to closing price of Rs 1448 as on 25th June 2021.
  • Thyrocare board approves share buyback

    10 Sep 2018 , 11:56AM Thyrocare Technologies board approved buyback of 8.63 lakh shares at Rs. 730 per share (14% upside from closing on Sep 07,2018) aggregating to Rs. 63 crores; The buyback size is 14.97% of the aggregate paid-up share capital –Positive for Thyrocare; buyback is open only for public shareholders (promoters not allowed); Objective of buyback is to return surplus cash to shareholders.

Key fundamentals

Evaluate the intrinsic value of Thyrocare Technologies Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 560.68 537.1 533.58 521.04 520.7
Liabilities 560.68 537.1 533.58 521.04 520.7
Equity 159.17 52.99 52.95 52.93 52.9
Gross Profit 256.33 187.02 133.88 112.01 230.83
Net Profit 148.81 95.78 71.14 56.97 152.05
Cash From Operating Activities 206.07 190.76 155.19 120.02 105.68
NPM(%) 19.21 15.12 13.57 11.71 27.07
Revenue 774.27 633.1 524.02 486.46 561.53
Expenses 517.94 446.08 390.14 374.45 330.7
ROE(%) 22.27 14.33 10.64 8.52 22.75

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
7 70 3.01 470.7
24 Oct 2025 7 70 3.01 1264.6
25 Jul 2025 21 210 3.01 769.2
16 Aug 2024 18 180 3.01 647.25
20 Apr 2023 18 180 3.01 475.9
11 May 2022 15 150 3.01 770.95
17 Jun 2021 15 150 3.01 1063.6
12 Nov 2020 10 100 3.01 1137.65
21 Nov 2019 5 50 3.01 558.55
14 Aug 2019 20 200 3.01 434.7
02 Aug 2018 5 50 3.01 668.95
15 Feb 2018 5 50 3.01 676.2
03 Aug 2017 5 50 3.01 735.45
08 Feb 2017 5 50 3.01 709
01 Sep 2016 2.5 25 3.01 602

Peers

Other companies within the same industry or sector that are comparable to Thyrocare Technologies Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 705.80 -0.07 0.00 266.16 -26.19 0.71
Lotus Eye Hospital and Institute Ltd 109.19 1.26 352.23 969.84 3.55 0.00
Vaishali Pharma Ltd 7.00 0.14 0.00 6084.10 3.13 0.00
Astec Lifesciences Ltd 771.80 4.77 0.00 914.58 -363.15 0.00

Company Info

The Company was incorporated as Thyrocare Technologies Limited on January 28, 2000 at Mumbai as a public limited company under the Companies Act, 1956. the Company was issued a certificate of commencement of business from the RoC on March 7, 2000. Major events and milestones of the Company : 2000 -The Company was incorporated in the name and style of "Thyrocare Technologies Limited' and received a certificate for commencement of operations. 2001 -The Company received ISO 9001 certification. -The Company commenced commercial operations under the brand name 'Thyrocare' pursuant to the acquisition of business of TDPL and TBPL (which were incorporated in 1996). 2005 -The Company received NABL accreditation. 2006 -The Company issued certain fully convertible debentures aggregating to 250 million to BCCL. 2007 -The Company receives accreditation from the College of American Pathologists (CAP). 2010 -The Company issued certain compulsorily convertible debentures aggregating to 250 million to Agalia. Agalia also acquired certain Equity Shares aggregating to 1,250 million from the Promoters and certain other persons. -The Company launched wellness packages under the brand name "Aarogyam". 2011 -The Company migrated to "total laboratory automation system" installed by Siemens for efficient handling of increasing volumes. 2012 -NVP acquired certain Equity Shares aggregating to 1,200 million from certain entities. 2013 -EIF acquired certain Equity Shares from Agalia. -The Subsidiary commenced operations at the PET-CT centres at Navi Mumbai and conducted over 1,000 scans in the first year of operation. 2014 -The Company had installed, India's first and the world's longest track automation system for seamless sample movements from Siemens Limited. -The Company commissioned the operations in medical cyclotron facility in Navi Mumbai. -The Subsidiary commenced operations at the PET-CT centres in New Delhi and Hyderabad and the PET-CT centres at New Delhi conducted over 1,000 scans in the first year of operations. 2015 -The Company opened RPLs in Delhi, Coimbatore, Hyderabad and Kolkata to expand its coverage and volume of tests and samples processed daily. -The Company acquired the equipment for testing of water samples and commenced operating the equipment under the brand name "WHATERS". These tests, at present include physical and chemical testing, elements testing, microbiology testing, pesticide testing and volatile organic compounds testing. -The Subsidiary has completed over 10,000 scans at the PET-CT centres in New Delhi, over 10,000 scans at the PET-CT centres in Navi Mumbai from the date of inception and over 1,000 scans at the PET-CT centres in Hyderabad since inception. 2016 -Thyrocare Technologies are listed and admitted to dealings on the Exchange in the list of 'B' Group Securities. 2024 -Thyrocare Technologies Completed acquisition of Think Health Diagnostic Private Limited. 2025-The Company has issued Bonus Shares in the Ratio of 2:1.

The Company was incorporated as Thyrocare Technologies Limited on January 28, 2000 at Mumbai as a public limited company under the Companies Act, 1956. the Company was issued a certificate of commencement of business from the RoC on March 7, 2000. Major events and milestones of the Company : 2000 -The Company was incorporated in the name and style of "Thyrocare Technologies Limited' and received a certificate for commencement of operations. 2001 -The Company received ISO 9001 certification. -The Company commenced commercial operations under the brand name 'Thyrocare' pursuant to the acquisition of business of TDPL and TBPL (which were incorporated in 1996). 2005 -The Company received NABL accreditation. 2006 -The Company issued certain fully convertible debentures aggregating to 250 million to BCCL. 2007 -The Company receives accreditation from the College of American Pathologists (CAP). 2010 -The Company issued certain compulsorily convertible debentures aggregating to 250 million to Agalia. Agalia also acquired certain Equity Shares aggregating to 1,250 million from the Promoters and certain other persons. -The Company launched wellness packages under the brand name "Aarogyam". 2011 -The Company migrated to "total laboratory automation system" installed by Siemens for efficient handling of increasing volumes. 2012 -NVP acquired certain Equity Shares aggregating to 1,200 million from certain entities. 2013 -EIF acquired certain Equity Shares from Agalia. -The Subsidiary commenced operations at the PET-CT centres at Navi Mumbai and conducted over 1,000 scans in the first year of operation. 2014 -The Company had installed, India's first and the world's longest track automation system for seamless sample movements from Siemens Limited. -The Company commissioned the operations in medical cyclotron facility in Navi Mumbai. -The Subsidiary commenced operations at the PET-CT centres in New Delhi and Hyderabad and the PET-CT centres at New Delhi conducted over 1,000 scans in the first year of operations. 2015 -The Company opened RPLs in Delhi, Coimbatore, Hyderabad and Kolkata to expand its coverage and volume of tests and samples processed daily. -The Company acquired the equipment for testing of water samples and commenced operating the equipment under the brand name "WHATERS". These tests, at present include physical and chemical testing, elements testing, microbiology testing, pesticide testing and volatile organic compounds testing. -The Subsidiary has completed over 10,000 scans at the PET-CT centres in New Delhi, over 10,000 scans at the PET-CT centres in Navi Mumbai from the date of inception and over 1,000 scans at the PET-CT centres in Hyderabad since inception. 2016 -Thyrocare Technologies are listed and admitted to dealings on the Exchange in the list of 'B' Group Securities. 2024 -Thyrocare Technologies Completed acquisition of Think Health Diagnostic Private Limited. 2025-The Company has issued Bonus Shares in the Ratio of 2:1.

Parent Organisation

Thyrocare Technologies Ltd.

Founded

28/01/2000

Managing Director

Mr.Rahul Guha

NSE Symbol

THYROCAREEQ

FAQ

OPEN FREE* DEMAT ACCOUNT